Company Info
| Industry | Pharmaceuticals: Generic |
|---|---|
| Sector | Health Technology |
| Employees | 248 |
| CEO | Ms. Zhi Lin Li |
| Address | No.17, Jinpan Road 2nd Floor, Haikou, HA 570216 |
|---|---|
| Phone | 86.898.6681.173 |
| Website | www.chinapharmaholdings.com |
China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. The firm’s product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Others, Comprehensive Healthcare and Protective Products. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.
Competitors
| Company Name | 3 Month %Change |
1 Year %Change |
|---|---|---|
| China Pharma Holdings, Inc. | -26.05% | 11.00% |
| BellRing Brands, Inc. | -23.22% | 17.51% |
| ImmunoGen, Inc. | -16.49% | -9.25% |
| Heron Therapeutics, Inc. | -18.03% | -47.00% |
| Singular Genomics Systems, Inc. | -23.64% | n/a |
Statement Summary
as of 4:10 ET PM 11/24/2021| Total Assets (MRQ) | 18.2 M |
|---|---|
| Total Liabilities (MRQ) | 11.3 M |
| Shareholders’ Equity (MRQ) | 6.9 M |
| Total Revenue (Annual) | 2.0 M |
| Net Income (Annual) | -826.7 K |
Earnings And Estimates
as of 4:10 ET PM 11/24/2021
| Current Qtr EPS Estimate | n/a |
|---|---|
| Current FY EPS Estimate | n/a |
| Long Term EPS Growth Estimate | 10.00 |
| Next Expected Earnings Date | // |
CPHI vs S&P 500
as of 11/24/2021| Relative To S&P 500 |
CPHI | |
|---|---|---|
| 4 Weeks | n/a | n/a |
| 12 Weeks | n/a | n/a |
| YTD | n/a | n/a |
Earnings Surprises
as of 4:10 ET PM 11/24/2021| Fiscal Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 09/2011 | 0.12 | 0.08 | -33.33% |
| 06/2011 | 0.12 | 0.12 | 0.00% |
| 03/2011 | 0.12 | 0.12 | +4.35% |
| 12/2010 | 0.16 | 0.21 | +34.04% |
| 09/2010 | 0.13 | 0.13 | +2.63% |
| 06/2010 | 0.11 | 0.12 | +9.09% |
| 03/2010 | 0.11 | 0.10 | -9.09% |
| 12/2009 | 0.14 | 0.12 | -11.11% |
Financial Strength
as of 4:10 ET PM 11/24/2021| Pre-Tax Margin | -41.78 |
|---|---|
| Net Margin | 0.68 |
| Operating Margin | -38.53 |
| Return On Equity | -49.31 |
| Return On Assets | -18.46 |
| Inventory Turnover (TTM) | 2.71 |
| Sales Growth (MRQ) | -11.79 |
Ratios
as of 4:10 PM ET 11/24/2021| Price/Earnings (TTM) | n/a |
|---|---|
| Price/Book (MRQ) | 3.73 |
| Price/Cash Flow (TTM) | 87.10 |
| Book Value (MRQ) | 0.14 |
| Quick Ratio (MRQ) | 0.10 |
| Current Ratio (MRQ) | 0.40 |
| Total Debt/Equity (MRQ) | 1.10 |
Short Interest
as of 1:10 PM ET 11/26/2021| % Short - 2.88% | |
| % Remaining Float - 97.12% |
| Current | Last Month | |
|---|---|---|
| Short Interest Date | 11/15/2021 | 10/29/2021 |
| Short Interest Shares | 587,308 | 1,068,055 |
| Short Interest Ratio | 1.4 | 0.2 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
|---|---|---|
Balance Sheet
| M Y | ||||
|---|---|---|---|---|
| ASSETS | ||||
| Cash And Equivalents | 0,0.00 | |||
| Receivables | 0,0.00 | |||
| Inventories | 0,0.00 | |||
| Other Current Assets | 0,0.00 | |||
| Total Current Assets | 0,0.00 | |||
| Property, Plant & Equipment, Gross | 0,0.00 | |||
| Accumulated Depreciation & Depletion | 0,0.00 | |||
| Property, Plant & Equipment, Net | 0,0.00 | |||
| Intangibles | 0,0.00 | |||
| Other Non-Current Assets | 0,0.00 | |||
| Total Non-Current Assets | 0,0.00 | |||
| TOTAL ASSETS | 0,0.00 | |||
| Liabilities & Shareholder Equity | ||||
| Accounts Payable | 0,0.00 | |||
| Short Term Debt | 0,0.00 | |||
| Total Current Liabilities | 0,0.00 | |||
| Long Term Debt | 0,0.00 | |||
| Deferred Income Taxes | 0,0.00 | |||
| Other Non-Current Liabilities | 0,0.00 | |||
| Minority Interest | 0,0.00 | |||
| Total Non-Current Liabilities | 0,0.00 | |||
| Preferred Stock Equity | 0,0.00 | |||
| Common Stock Equity | 0,0.00 | |||
| Common Par | 0,0.00 | |||
| Additional Paid In Capital | 0,0.00 | |||
| Cumulative Translation Adjustment | 0,0.00 | |||
| Retained Earnings | 0,0.00 | |||
| Treasury Stock | 0,0.00 | |||
| Other Equity Adjustments | 0,0.00 | |||
| Total Capitalization | 0,0.00 | |||
| TOTAL EQUITY | 0,0.00 | |||
| TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
| Total Common Shares Outstanding | 0,0.00 | |||
| Preferred Shares | 0,0.00 | |||
| Treasury Shares | 0,0.00 | |||
| Basic Weighted Shares Outstanding | 0,0.00 | |||
| Diluted Weighted Shares Outstanding | 0,0.00 | |||
| Number Of Employees | 0,0.00 | |||
| Number Of Part-Time Employees | 0,0.00 | |||
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
|---|---|---|
Income Statement
| M Y | |
|---|---|
| Sales | 0,0.00 |
| Cost Of Sales | 0,0.00 |
| Gross Operating Profit | 0,0.00 |
| Selling, General, And Administrative Expenses | 0,0.00 |
| Research & Development | 0,0.00 |
| Operating Income Before D & A (EBITDA) | 0,0.00 |
| Depreciation & Amortization | 0,0.00 |
| Interest Income | 0,0.00 |
| Other Income - Net | 0,0.00 |
| Special Income / Charges | 0,0.00 |
| Total Income Before Interest Expenses (EBIT) | 0,0.00 |
| Interest Expense | 0,0.00 |
| Pre-Tax Income | 0,0.00 |
| Income Taxes | 0,0.00 |
| Minority Interest | 0,0.00 |
| Net Income From Continuing Operations | 0,0.00 |
| Net Income From Discontinued Operations | 0,0.00 |
| Net Income From Total Operations | 0,0.00 |
| Extraordinary Income/Losses | 0,0.00 |
| Income From Cum. Effect Of Acct. Change | 0,0.00 |
| Income From Tax Loss Carryforward | 0,0.00 |
| Other Gains / Losses | 0,0.00 |
| Total Net Income | 0,0.00 |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Preferred Dividends | 0,0.00 |
| Net Income Available To Common | 0,0.00 |
| Basic EPS From Continuing Ops. | 0,0.00 |
| Basic EPS From Discontinued Ops. | 0,0.00 |
| Basic EPS From Total Operations | 0,0.00 |
| Basic EPS From Extraordinary Inc. | 0,0.00 |
| Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
| Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
| Basic EPS From Other Gains (Losses) | 0,0.00 |
| Basic EPS, Total | 0,0.00 |
| Basic Normalized Net Income/Share | 0,0.00 |
| EPS From Continuing Ops. | 0,0.00 |
| EPS From Discontinued Ops | 0,0.00 |
| EPS From Total Ops. | 0,0.00 |
| EPS From Extraord. Inc. | 0,0.00 |
| EPS From Cum Effect of Accounting Change | 0,0.00 |
| EPS From Tax Loss Carfd. | 0,0.00 |
| EPS From Other Gains (L) | 0,0.00 |
| EPS, Total | 0,0.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
|---|---|---|
Cash Flow Statement
| M Y | ||||
|---|---|---|---|---|
| Cash Flow From Operating Activities | ||||
| Net Income (Loss) | 0,0.00 | |||
| Operating Gains/Losses | 0,0.00 | |||
| Gross Operating Profit | 0,0.00 | |||
| (Increase) Decrease In Receivables | 0,0.00 | |||
| (Increase) Decrease In Inventories | 0,0.00 | |||
| (Increase) Decrease In Other Current Assets | 0,0.00 | |||
| (Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
| (Increase) Decrease In Other Working Capital | 0,0.00 | |||
| Other Non-Cash Items | 0,0.00 | |||
| Net Cash From Continuing Operations | 0,0.00 | |||
| Net Cash From Discontinued Operations | 0,0.00 | |||
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 0,0.00 | |||
| Sale Of Property, Plant & Equipment | 0,0.00 | |||
| Cash Used For Investing Activities | ||||
| Sale Of Short-Term Investments | 0,0.00 | |||
| Purchases Of Property, Plant & Equipment | 0,0.00 | |||
| Acquisitions | 0,0.00 | |||
| Purchases Of Short-Term Investments | 0,0.00 | |||
| Other Cash From Investing Activities | 0,0.00 | |||
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 0,0.00 | |||
| Issuance Of Debt | 0,0.00 | |||
| Cash Used For Financing Activities | ||||
| Issuance Of Capital Stock | 0,0.00 | |||
| Repayment Of Long-Term Debt | 0,0.00 | |||
| Repurchase Of Capital Stock | 0,0.00 | |||
| Payment Of Cash Dividends | 0,0.00 | |||
| Other Financing Charges, Net | 0,0.00 | |||
| Net Cash From Financing Activities | 0,0.00 | |||
| Effect Of Exchange Rate Changes | 0,0.00 | |||
| Net Change In Cash & Cash Equivalents | 0,0.00 | |||
Earnings Estimates
as of 4:10 ET PM 11/24/2021| Current Qtr (12/1969) |
Next Qtr (12/1969) |
|
|---|---|---|
| Consensus Estimate | n/a | n/a |
| # of Estimates | n/a | n/a |
| High Estimate | n/a | n/a |
| Low Estimate | n/a | n/a |
| Year Ago EPS | n/a | n/a |
| Year Over Year Growth Estimate | n/a | n/a |
| Current Yr (12/1969) |
Next Yr (12/1969) |
|
|---|---|---|
| Consensus Estimate | n/a | n/a |
| # of Estimates | n/a | n/a |
| High Estimate | n/a | n/a |
| Low Estimate | n/a | n/a |
| Year Ago EPS | n/a | n/a |
| Year Over Year Growth Estimate | n/a | n/a |
| Current Qtr (12/1969) |
Next Qtr (12/1969) |
Current Year (12/1969) |
Next Year (12/1969) |
|
|---|---|---|---|---|
| Consensus Estimate | n/a | n/a | n/a | n/a |
| # of Estimates | n/a | n/a | n/a | n/a |
| High Estimate | n/a | n/a | n/a | n/a |
| Low Estimate | n/a | n/a | n/a | n/a |
| Year Ago EPS | n/a | n/a | n/a | n/a |
| Year Over Year Growth Estimate | n/a | n/a | n/a | n/a |
Insider Information Summary
as of 10/31/2021| % Insiders - 53.06% | |
| % Remaining Total Shares - 46.94% |
| Current | 1 Month | |
|---|---|---|
| Net Insider Transaction | 1.76 M | 1.76 M |
| Shares Bought | 1.76 M | 1.76 M |
| Shares Sold | 0.00 | 0.00 |
Insider Activity
| Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Learn to Trade Like a Pro
Master The Market with the Help of Our Financial Experts
LATEST NEWS
3 Stocks Pushing The Drugs Industry Lower
Aug 4, 2015 4:33 PM EDT
Latest News
3 Drugs Stocks Nudging The Industry Higher
Jul 31, 2015 4:33 PM EDT
3 Health Care Stocks Pushing The Sector Higher
Jul 29, 2015 4:52 PM EDT
3 Stocks Improving Performance Of The Drugs Industry
Jul 29, 2015 4:52 PM EDT
3 Stocks Pushing The Drugs Industry Lower
Mar 10, 2015 4:35 PM EDT
3 Stocks Pushing The Drugs Industry Lower
Mar 3, 2015 3:32 PM EST
3 Drugs Stocks Nudging The Industry Higher
Feb 13, 2015 4:32 PM EST
3 Health Care Stocks Pushing The Sector Higher
Feb 12, 2015 4:32 PM EST
3 Stocks Advancing The Health Care Sector
Feb 6, 2015 4:32 PM EST
3 Stocks Boosting The Drugs Industry Higher
Feb 6, 2015 4:32 PM EST
3 Health Care Stocks Moving The Sector Upward
Feb 5, 2015 4:32 PM EST
3 Drugs Stocks Nudging The Industry Higher
Feb 5, 2015 4:31 PM EST
3 Stocks Pushing The Health Care Sector Lower
Feb 4, 2015 4:32 PM EST
3 Stocks Moving The Drugs Industry Upward
Jan 29, 2015 4:32 PM EST
3 Stocks Pushing The Drugs Industry Lower
Jan 28, 2015 4:32 PM EST
3 Stocks Pushing The Drugs Industry Lower
Jan 23, 2015 4:32 PM EST
3 Drugs Stocks Pushing The Industry Higher
Jan 20, 2015 4:32 PM EST
3 Drugs Stocks Driving The Industry Higher
Jan 8, 2015 4:32 PM EST
3 Health Care Stocks Moving The Sector Upward
Nov 26, 2014 3:32 PM EST
3 Stocks Moving The Drugs Industry Upward
Nov 26, 2014 3:32 PM EST
3 Stocks Pushing The Drugs Industry Lower
Nov 19, 2014 3:32 PM EST
3 Stocks Pushing The Drugs Industry Lower
Nov 11, 2014 3:32 PM EST
3 Health Care Stocks Pushing The Sector Higher
Oct 28, 2014 4:33 PM EDT
3 Health Care Stocks Pushing Sector Growth
Oct 24, 2014 4:33 PM EDT
3 Drugs Stocks Moving The Industry Upward
Oct 24, 2014 4:33 PM EDT
Recent Articles from TheStreet
Walmart CFO Brett Biggs Leaving After 22 Years
Walmart says Biggs stay on as CFO until a successor is named and will remain as an associate until he leaves in January 2023.
Bristol Myers Stock Falls Despite Positive News on Psoriasis Drug
Bristol Myers shares fall after the FDA accepts its psoriasis-treating deucravacitinib drug application, and European regulators also validate its application.
Best Buy, Big-Box Store Inventory Strong, Roku Demand High: Wedbush
Wedbush finds no shortage of in-store inventory for consumer electronics. And it says Roku products are in strong demand.
Twitter Stock Leaps Amid Report CEO Jack Dorsey Will Step Down
Twitter co-founder Jack Dorsey is set to step-down as CEO of the microblogging website, CNBC reported Monday.
Wells Fargo Bullish on Quality Stocks, Despite Omicron
'We do not recommend de-risking into weakness,' Chris Harvey, head of equity strategy for Wells, writes in a commentary.
Amazon Invests in Bypassing Retail Supply Chain Issues
Amazon has built more than 450 new facilities nationwide in recent months in order to beat supply chain issues.
Cryptocurrency Price Check: Bitcoin Bounces Back After Omicron Scare
Bitcoin 'is leading the market back from the depths of despair,' a cryptocurrency analyst says.
Premarket Movers Monday: Moderna, Zoom Video
Stock futures rose Monday amid travel curbs tied to the omicron Covid variant.
Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant
Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.
Tech Stocks Lead As Omicron Fears Linger; Pfizer, Moderna, Twitter Move Higher - Stock Market Today
Wall Street looks to rebound from the worst Black Friday session on record Monday as investors continue to track developments in the spread of the newly-discovered Omicron variant.